CARD9 Antikörper (AA 101-200) (Cy3)
Kurzübersicht für CARD9 Antikörper (AA 101-200) (Cy3) (ABIN886515)
Target
Alle CARD9 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 101-200
-
Verwendungszweck
- CARD9 Polyclonal Antibody, Cy3 Conjugated
-
Homologie
- Human,Dog,Horse
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human CARD9
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- WB(1:300-5000), IF(IHC-P)(1:50-200), IF(IHC-F)(1:50-200), IF(ICC)(1:50-200)
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- CARD9 (Caspase Recruitment Domain Family, Member 9 (CARD9))
-
Andere Bezeichnung
- CARD9
-
Hintergrund
-
Synonyms: CARD9,CARD9_HUMAN,Caspase recruitment domain family member 9,Caspase recruitment domain-containing protein 9,hCARD9.
Background: Activates NF-kappa-B via BCL10.Tissue specificity, Highly expressed in spleen. Also detected in liver, placenta, lung, peripheral blood leukocytes and in brain.
-
Gen-ID
- 64170
-
Pathways
- Activation of Innate immune Response
Target
-